

Remarks

Upon entry of the foregoing amendment, claims 1-36 are pending in the application, with claims 1, 10, 16, 29, 31 and 32 being the independent claims. Claims 1 and 10 have been amended to correct the spelling of "sufhydryl." Claim 25 has been amended to correct the lettering sequence for the list of R²⁴ and R²⁵ substituents. Claims 28, 30 and 33 have been amended to add a period at the end of the claim. Claims 34 and 35 have been amended to change their dependencies. These changes are believed to introduce no new matter, and their entry is respectfully requested.


The specification has been amended to include an abstract on a separate page. Support for the amendment adding the abstract to the specification can be found in the abstract printed on the published PCT Application No. PCT/US2003/031466, which is relied upon for the benefit under 35 U.S.C. § 120. No new matter has been added by way of this amendment.

Conclusion

Prompt and favorable consideration of this Preliminary Amendment is respectfully requested. Applicants believe the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Bryan L. Skelton
Agent for Applicants
Registration No. 50,893

Date: March 31, 2005

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

380294_1.DOC

Biphenyls and Fluorenes as Imaging Agents in Alzheimer's Disease

Abstract

This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.